An Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Vilaprisan in Subjects With Decreased Renal Function in Comparison With Matched Subjects With Normal Renal Function
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Vilaprisan (Primary)
- Indications Endometriosis; Uterine leiomyoma
- Focus Pharmacokinetics
- Sponsors Bayer
- 07 Jan 2019 Planned End Date changed from 28 Nov 2018 to 31 Jan 2019.
- 29 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.